The Drug Administration has approved the new coronary vaccine Phase II clinical, with BioNTech supplying at least 100 million doses next year

BioNTech is committed to supplying Chinese mainland 100 million doses of new crown vaccine products to the united States by 2021.
December 17, Fosun Pharma Global Research and Development Center President and Chief Medical Officer Hui Aimin in an interview with reporters revealed that, with the approval of the State Drug Administration, Fosun Pharma in Jiangsu on November 24 to carry out mRNA new coronary nucleic acid vaccine BNT162b2 Phase II clinical trials.
that at least 100 million doses of the vaccine, developed by Fosun Pharma in international cooperation, are expected to be available to the domestic public by 2021.
yesterday, Fosun Pharma announced that it had reached an agreement with BioNTech to ensure "adequate supply" of vaccines in China.
's announcement showed that under the supply agreement, the first 50 million doses of the new crown vaccine products were supplied with an advance payment of 250 million euros, of which 125 million euros were paid by December 30, 2020, with the balance paid after the products were approved for sale in Chinese mainland.
BioNTech has pledged to supply no less than 100 million doses of new crown vaccine products to Chinese mainland by 2021, with BioNTech's new mRNA vaccine product approved for Chinese mainland and other conditions met, Reuters reported.
, according to foreign media reports, BionTech is currently selling two new crown vaccines in the United States for 33 euros.
the mRNA vaccine, launched jointly with Pfizer, has been approved in countries such as the United States, the United Kingdom and Singapore.
Lin Yiling Source: Great Health Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here